Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."
The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.
OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.
The investment bank cut its price target on Quest's shares and noted recently passed legislation that it believes will put pricing pressure on the company.